# Prednisone

```text
DRUG INFORMATION

  ADULT
    - The timing of administration should take into account the delayed-release
      pharmacokinetics and the disease or condition being treated ( 2 , 12.1 ): Initial
      dose: Prednisone delayed-release tablets 5 mg administered once per day.
      Source: US FDA label for prednisone (Prednisone delayed release), section 'dosage
      and administration', retrieved 2026-08-29
    - The initial dosage of prednisone delayed-release tablets may vary from 5 to 60 mg
      per day depending on the specific disease entity being treated.
      Source: US FDA label for prednisone (Prednisone delayed release), section 'dosage
      and administration', retrieved 2026-08-29
    - Prednisone delayed-release tablets should be taken daily with food. [see Clinical
      Pharmacology (12.3) ] Prednisone delayed-release tablets should not be broken,
      divided, or chewed because the delayed release of prednisone is dependent on an
      intact coating [see Description (11)] .
      Source: US FDA label for prednisone (Prednisone delayed release), section 'dosage
      and administration', retrieved 2026-08-29

  CHILD
    - The efficacy and safety of prednisone in the pediatric population are based on the
      well-established course of effect of corticosteroids which is similar in pediatric
      and adult populations. Published studies provide evidence of efficacy and safety
      in pediatric patients for the treatment of nephrotic syndrome (> 2 years of age),
      and aggressive lymphomas and leukemias (> 1 month of age).
      Source: US FDA label for prednisone (Prednisone delayed release), section
      'pediatric use', retrieved 2026-08-29
    - Individualize dosing based on disease severity and patient response. The timing of
      administration should take into account the delayed-release pharmacokinetics and
      the disease or condition being treated ( 2 , 12.1 ): Initial dose: Prednisone
      delayed-release tablets 5 mg administered once per day.
      Source: US FDA label for prednisone (Prednisone delayed release), section 'dosage
      and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - These agents should be used with caution in patients with congestive heart
      failure, hypertension, or renal insufficiency.
      Source: US FDA label for prednisone (Prednisone delayed release), section
      'warnings and cautions', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for prednisone (Prednisone delayed
      release), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Based on findings from human and animal studies, corticosteroids,
      including prednisone delayed-release tablets, can cause fetal harm when
      administered to a pregnant woman (see Data ) [see Warnings and Precautions (5.10)
      ].
      Source: US FDA label for prednisone (Prednisone delayed release), section
      'pregnancy', retrieved 2026-08-29
    - Published epidemiological studies suggest a small but inconsistent increased risk
      of orofacial clefts with use of corticosteroids during the first trimester.
      Source: US FDA label for prednisone (Prednisone delayed release), section
      'pregnancy', retrieved 2026-08-29
    - Intrauterine growth restriction and decreased birth weight have also been reported
      with maternal use of corticosteroids during pregnancy; however, the underlying
      maternal condition may also contribute to these risks (see Clinical Considerations
      ).
      Source: US FDA label for prednisone (Prednisone delayed release), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Prednisone delayed-release tablets was not formally evaluated in animal
      reproduction studies. 8.2 Lactation Risk Summary Prednisolone has been found to be
      present in human milk following administration to lactating women.
      Source: US FDA label for prednisone (Prednisone delayed release), section 'use in
      specific populations', retrieved 2026-08-29
    - No adverse effects in the breastfed infant have been reported following maternal
      exposure of prednisolone during breastfeeding.
      Source: US FDA label for prednisone (Prednisone delayed release), section 'use in
      specific populations', retrieved 2026-08-29
    - High doses of corticosteroids administered to lactating women for long periods
      could potentially produce problems in the breastfed infant including growth and
      development and interfere with endogenous corticosteroid production (see Clinical
      Considerations ) [see Use in Specific Populations (8.4) ].
      Source: US FDA label for prednisone (Prednisone delayed release), section 'use in
      specific populations', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)